Cargando…

Nephrology Consultation for Severe SGLT2 Inhibitor-Induced Ketoacidosis in Type 2 Diabetes: Case Report

Euglycemic diabetic ketoacidosis (euDKA) related to sodium-glucose cotransporter 2 inhibitor (SGLT2-I), despite being reported as consistent, though infrequent, adverse effect in all trials on SGLT2-I in type 2 diabetes mellitus (T2D), still remains poorly known in the real world. On the other hand,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nappi, Felice, La Verde, Antonietta, Carfora, Giovanni, Garofalo, Carlo, Provenzano, Michele, Sasso, Ferdinando Carlo, De Nicola, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723212/ https://www.ncbi.nlm.nih.gov/pubmed/31405158 http://dx.doi.org/10.3390/medicina55080462

Ejemplares similares

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
por: Garofalo, Carlo, et al.
Publicado: (2019)

Nephroprotection by SGLT2 Inhibition: Back to the Future?
por: De Nicola, Luca, et al.
Publicado: (2020)

Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care
por: Provenzano, Michele, et al.
Publicado: (2018)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
por: Palmiero, Giuseppe, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care
por: De Nicola, Luca, et al.
Publicado: (2015)

Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
por: Chow, Erica, et al.
Publicado: (2023)

Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects
por: Pafundi, Pia Clara, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
por: Alhemeiri, Mohamed, et al.
Publicado: (2022)

SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
por: Iqbal, Qasim Zafar, et al.
Publicado: (2020)

A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Rao, Shiavax J, et al.
Publicado: (2022)

THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023)

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
por: Giugliano, Dario, et al.
Publicado: (2020)

Current Management of Hyperkalemia in Non-Dialysis CKD: Longitudinal Study of Patients Receiving Stable Nephrology Care
por: Borrelli, Silvio, et al.
Publicado: (2021)

Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor
por: Miyauchi, Masaaki, et al.
Publicado: (2017)

SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report
por: Wang, Katherine M., et al.
Publicado: (2020)

Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2‐inhibitor therapy
por: Westcott, Gregory P., et al.
Publicado: (2020)

Diabetic Euglycemic Ketoacidosis Induced by Oral Antidiabetics Type SGLT2i
por: Velasco de Cos, Guillermo, et al.
Publicado: (2021)

Lithium Nephrotoxicity: When Is the Time for Nephrology Consultation?
por: SAVAJ, Shokoufeh, et al.
Publicado: (2016)

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
por: Ogawa, Wataru, et al.
Publicado: (2015)

Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats
por: Perry, Rachel J., et al.
Publicado: (2019)

Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis
por: Rafey, Mohammed Faraz, et al.
Publicado: (2019)

PSUN190 Is Euglycemic Diabetic Ketoacidosis an Underrecognized Risk of SGLT2 Inhibitor Utilization?
por: Block, Romy, et al.
Publicado: (2022)

THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
por: Viera Feliciano, Natalia, et al.
Publicado: (2023)

Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease
por: Provenzano, Michele, et al.
Publicado: (2022)

Clinical Characteristics and Outcomes of Diabetic Ketoacidosis in Patients With Type 2 Diabetes using SGLT2 Inhibitors
por: Almazrouei, Raya, et al.
Publicado: (2023)

MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 Inhibitors- an Under-recognized Diagnosis
por: Chhabra, Sarah, et al.
Publicado: (2020)

Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis
por: Dutta, Siddhartha, et al.
Publicado: (2022)

A Case Report of Euglycemic Diabetic Ketoacidosis in the Setting of Keto Diet and SGLT-2 Inhibitors
por: Marenych, Nadiia, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis Secondary to SGLT2-inhibitor Use in Combination With a Ketogenic Diet
por: Hester, Joi C, et al.
Publicado: (2021)

Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up
por: Sardu, Celestino, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors
por: Vitale, Rebecca J., et al.
Publicado: (2020)

ODP183 Diabetic Ketoacidosis Precipitated by Ketogenic Diet and SGLT-2 Inhibitor Use in an Individual with T2DM
por: Mason, Timothy, et al.
Publicado: (2022)

Green nephrology and eco-dialysis: a position statement by the Italian Society of Nephrology
por: Piccoli, Giorgina Barbara, et al.
Publicado: (2020)

Euglycemic Diabetic Ketoacidosis Precipitated by SGLT-2 Inhibitor Use, Pericarditis, and Fasting: A Case Report
por: Mendelsohn, Rebecca A., et al.
Publicado: (2020)

SAT-685 Euglycemic Diabetic Ketoacidosis in T1d: The Era of SGLT-2 Inhibitors and Keto-Diet
por: Castellanos-Diaz, Jessica, et al.
Publicado: (2020)

SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: a case report
por: Secinaro, Enzo, et al.
Publicado: (2022)

SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review
por: Mahfooz, Rabia Salman, et al.
Publicado: (2022)

ODP195 EUGLYCEMIC DIABETIC KETOACIDOSIS AFTER BARIATRIC SURGERY IN ASSOCIATION WITH USE OF SGLT2I.
por: Vaghasia, Nishit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eke25badn1qfunlvspq8aqq7ng